Veklury · pharmadog

Sign In Subscribe

Veklury · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 13, 2026

6 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (58)

Nov 28, 2041patentUS 11491169*PED
Nov 28, 2041patentUS 11491169*PED
Nov 28, 2041patentUS 11903953*PED
Nov 28, 2041patentUS 11903953*PED
Nov 28, 2041patentUS 11975012*PED
Nov 28, 2041patentUS 11975012*PED
May 28, 2041method-of-use (U-3835)US 11491169
May 28, 2041method-of-use (U-3833)US 11491169
May 28, 2041method-of-use (U-3834)US 11903953
May 28, 2041method-of-use (U-3836)US 11903953
May 28, 2041method-of-use (U-3836)US 11975012
May 28, 2041method-of-use (U-3834)US 11975012
Jan 10, 2039patentUS 10675296*PED
Jan 10, 2039patentUS 11266681*PED
Jan 10, 2039patentUS 11975017*PED
Jul 10, 2038formulationUS 10675296
Jul 10, 2038method-of-use (U-3831)US 11266681
Jul 10, 2038formulationUS 11975017
Mar 16, 2037patentUS 10695361*PED
Mar 16, 2037patentUS 10695361*PED
Mar 16, 2037patentUS 11007208*PED
Mar 16, 2037patentUS 11007208*PED
Mar 16, 2037patentUS 11382926*PED
Mar 16, 2037patentUS 11382926*PED
Sep 16, 2036method-of-use (U-3832)US 10695361
Sep 16, 2036method-of-use (U-3830)US 10695361
Sep 16, 2036method-of-use (U-3830)US 11007208
Sep 16, 2036method-of-use (U-3832)US 11007208
Sep 16, 2036method-of-use (U-3832)US 11382926
Sep 16, 2036method-of-use (U-3829)US 11382926
Apr 29, 2036patentUS 9724360*PED
Apr 29, 2036patentUS 9724360*PED
Apr 29, 2036patentUS 9949994*PED
Apr 29, 2036patentUS 9949994*PED
Oct 29, 2035compositionUS 9724360
Oct 29, 2035compositionUS 9724360
Oct 29, 2035compositionUS 9949994
Oct 29, 2035compositionUS 9949994
Jun 8, 2032patentUS 11492353*PED
Jun 8, 2032patentUS 11492353*PED
Mar 16, 2032patentUS 10065958*PED
Mar 16, 2032patentUS 10065958*PED
Dec 8, 2031compositionUS 11492353
Dec 8, 2031compositionUS 11492353
Sep 16, 2031compositionUS 10065958
Sep 16, 2031compositionUS 10065958
Mar 6, 2030patentUS 8008264*PED3.7y
Mar 6, 2030patentUS 8008264*PED3.7y
Oct 22, 2029patentUS 8318682*PED3.3y
Oct 22, 2029patentUS 8318682*PED3.3y
Oct 22, 2029patentUS RE46762*PED3.3y
Oct 22, 2029patentUS RE46762*PED3.3y
Sep 6, 2029compositionUS 80082643.2y
Sep 6, 2029compositionUS 80082643.2y
Apr 22, 2029compositionUS 83186822.8y
Apr 22, 2029compositionUS 83186822.8y
Apr 22, 2029compositionUS RE467622.8y
Apr 22, 2029compositionUS RE467622.8y

FDA exclusivities (8)

Jan 13, 2027PEDPediatric (6mo bonus)190d
Jan 13, 2027PEDPediatric (6mo bonus)190d
Jul 13, 2026M-301Method (3y)6d
Jul 13, 2026M-301Method (3y)6d
Apr 22, 2026PEDPediatric (6mo bonus)
Apr 22, 2026PEDPediatric (6mo bonus)
Oct 22, 2025